Circulation|2026|Zhao Y
PMID: 41525434
15038 studies
BACKGROUND: Patients with overweight or obesity (OW/OB) are at increased risk for multimorbidity (≥2 obesity-related complications [ORCs]) and accompanying increases in mortality and excess costs. RESEARCH DESIGN AND METHODS: A retrospective, observa…
BACKGROUND AND AIMS: Semaglutide, a once-weekly injectable glucagon-like peptide, showed double-digit weight reduction with an acceptable safety profile in clinical trials and real-world studies. The efficacy and safety of non-comparable biotherapeut…
INTRODUCTION: The glucagon-like peptide-1 receptor agonist semaglutide may impact neuroinflammation and reduce neurodegeneration. We present baseline characteristics of participants enrolled in the evoke (NCT04777396) and evoke+ (NCT04777409) trials,…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained rapid popularity for both medical and consumer-directed weight loss. This growth has been accompanied by increased public discussion regarding facial aesthetic changes, com…
A 38-year-old man with poorly controlled type 2 diabetes mellitus and arterial hypertension on semaglutide presented with acute, painless, vision loss in the left eye. Ophthalmic examination revealed optic disc edema (ODE) in the left eye and optic d…
INTRODUCTION: GLP-1 receptor agonists, such as semaglutide, have demonstrated cardiovascular benefits in trials such as SELECT and SOUL. This study assesses the proportion of post-myocardial infarction patients who meet eligibility criteria to benefi…
Right ventricular (RV) dysfunction is a critical complication of pulmonary hypertension (PH) with limited treatment strategies. This study evaluated the therapeutic efficacy of the GLP-1 agonist semaglutide on RV dysfunction in rodent PH models, focu…
Cognitive impairments in depression, driven by both the illness per se and low-grade systemic inflammation, markedly reduce functional capacity and quality of life among patients who suffer. Findings from Badulescu et al.'s placebo-controlled trial r…
This paper introduces the concept and practice of "pharma-cology" which argues that future prescribers as well as established clinicians need to understand pharma sales tactics at a deeper level. The case of a drug rep from the late 1990s is highligh…
BACKGROUND: Precision medicine has transformed many areas in oncology. However, it remains largely unexplored in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), where there is a need for further innovative therapies. METHODS: T…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert cardiometabolic benefits beyond weight loss, yet their systemic proteomic mechanisms remain incompletely defined. We profiled short-term liraglutide-induced protein changes and co…
BACKGROUND: Ozempic (semaglutide) has received widespread attention for its appetite-suppressing effects, leading to extensive off-label use for weight loss. Although gastrointestinal side effects are well documented, less is known about how users as…
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver-related morbidity driven by systemic metabolic dysregulation. The recent approval of resmetirom and the clinical success of GLP-1 receptor agonists have heralded a ne…
AIMS: Evidence suggests sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce the onset/progression of dementia. The effect of the dual GLP1/GIP receptor agonist tirzepatide on dementia outcomes remains u…
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive condition characterized by excess hepatic fat accumulation in the absence of significant hepatocellular injury. Its more severe form, metabolic dys…
In 2024, a second brand of injectable semaglutide was marketed, authorized for the indication of weight loss, along with the first tirzepatide. Both are indicated as an adjunct to a low-calorie diet and increased physical activity for weight control,…
The year 2025 saw major advances in gastroenterology and hepatology. Having long been overshadowed by other chronic viral hepatitis, Hepatitis D now benefits from new therapeutic options, including bulevirtide, offering markedly improved clinical pro…
OBJECTIVE: This review compared antiobesity strategies-obesity management medications (OMM), endoscopic bariatric procedures (EBP), and metabolic bariatric surgery (MBS)-with lifestyle intervention, placebo, or no therapy (LSI/Pbo/NT). METHODS: This…